DERM (Journey Medical) Institutional Ownership: 45.83% (As of Jul. 07, 2026)


DERM Journey Medical Corp DERM
62 GF Score
Price $7.21
GF Value $4.20
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Journey Medical Institutional Ownership?

Journey Medical DERM +1.83% 62 Institutional Ownership is 45.83% as of Jul. 07, 2026. GuruFocus rates DERM with a GF Score™ of 62/100 and a GF Value™ of $4.20 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Journey Medical's institutional ownership is 45.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Journey Medical's Insider Ownership is 15.90%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Journey Medical's Float Percentage Of Total Shares Outstanding is 55.06%.

Journey Medical Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Journey Medical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Journey Medical Institutional Ownership Chart

Journey Medical Historical Data

The historical data trend for Journey Medical can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 11.66 12.56 12.41 14.30 11.22 11.29 19.72 19.51 19.46 17.33
DERM
62GF Score
Journey Medical Corp DERM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Journey Medical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 45.83% mean?
Journey Medical (DERM) has a Institutional Ownership of 45.83% as of Jul. 07, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Journey Medical and its competitors.
Is Journey Medical's Institutional Ownership too high?
Journey Medical's current Institutional Ownership is 45.83%. Overall, Journey Medical has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Institutional Ownership compare to LFCR and ANIK?
Journey Medical's Institutional Ownership of 45.83% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Journey Medical and its competitors. Journey Medical's current Institutional Ownership is 45.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.20, compared to a current price of $7.21 — trading 71.7% above its estimated fair value. The current Institutional Ownership is 45.83%. Journey Medical's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Journey Medical (DERM), the current Institutional Ownership is 45.83% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Journey Medical (DERM) Overvalued in 2026?

Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued. The current stock price of $7.21 is trading 71.7% above its estimated GF Value™ of $4.20. GuruFocus considers Journey Medical to be Significantly Overvalued.

Key valuation signals for DERM:

  • Institutional Ownership: 45.83%
  • GF Value™: $4.20 vs. price of $7.21 (71.7% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Journey Medical Business Description

Address 9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
62GF Score

Get the complete analysis for DERM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.21
Price
$4.20
GF Value